DK2061561T3 - Sammensætninger til behandling af cancer - Google Patents

Sammensætninger til behandling af cancer

Info

Publication number
DK2061561T3
DK2061561T3 DK07837326.3T DK07837326T DK2061561T3 DK 2061561 T3 DK2061561 T3 DK 2061561T3 DK 07837326 T DK07837326 T DK 07837326T DK 2061561 T3 DK2061561 T3 DK 2061561T3
Authority
DK
Denmark
Prior art keywords
cancer treatment
treatment compositions
compositions
cancer
treatment
Prior art date
Application number
DK07837326.3T
Other languages
English (en)
Inventor
Alan H Auerbach
Arie S Belldegrun
Original Assignee
Janssen Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2061561(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc
Application granted granted Critical
Publication of DK2061561T3 publication Critical patent/DK2061561T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DK07837326.3T 2006-08-25 2007-08-23 Sammensætninger til behandling af cancer DK2061561T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
PCT/US2007/018769 WO2008024484A1 (en) 2006-08-25 2007-08-23 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
DK2061561T3 true DK2061561T3 (da) 2013-10-07

Family

ID=38916904

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07837326.3T DK2061561T3 (da) 2006-08-25 2007-08-23 Sammensætninger til behandling af cancer
DK12160586.9T DK2478907T3 (da) 2006-08-25 2007-08-23 Sammensætninger til behandling af kræft

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12160586.9T DK2478907T3 (da) 2006-08-25 2007-08-23 Sammensætninger til behandling af kræft

Country Status (21)

Country Link
EP (3) EP2061561B1 (da)
JP (9) JP2010501575A (da)
KR (4) KR20150108946A (da)
CN (2) CN101528308A (da)
AU (6) AU2007287098C1 (da)
CA (1) CA2661422C (da)
CY (2) CY1115477T1 (da)
DK (2) DK2061561T3 (da)
ES (2) ES2428634T3 (da)
HK (1) HK1131577A1 (da)
HR (2) HRP20130961T1 (da)
HU (1) HUE054495T2 (da)
IL (3) IL197211A0 (da)
LT (1) LT2478907T (da)
NO (2) NO20091190L (da)
NZ (1) NZ597830A (da)
PL (2) PL2478907T3 (da)
PT (2) PT2061561E (da)
RS (2) RS62034B1 (da)
SI (2) SI2061561T1 (da)
WO (1) WO2008024484A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528308A (zh) * 2006-08-25 2009-09-09 库伽尔生物科技公司 治疗癌症的方法和组合物
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
AU2008319767B8 (en) * 2007-10-29 2014-01-09 Takeda Pharmaceutical Company Limited Pyrrolo [1,2-C] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
KR20140053836A (ko) 2011-01-11 2014-05-08 글락소스미스클라인 엘엘씨 조합물
RS56759B1 (sr) 2011-04-01 2018-04-30 Genentech Inc Kombinacija akt inhibitor jedinjenja i abiraterona za upotrebu pri terapeutskim tretiranjima
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
CA2872541A1 (en) * 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
CN104661658A (zh) 2012-09-26 2015-05-27 阿拉贡药品公司 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
SG10201709400VA (en) * 2013-03-15 2018-01-30 Iceutica Inc Abiraterone acetate formulation
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
KR20150138268A (ko) * 2013-04-04 2015-12-09 엑셀리시스, 인코포레이티드 암을 치료하기 위한 약물 병용요법
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
CN109674801A (zh) * 2013-10-01 2019-04-26 诺华股份有限公司 组合
KR101797415B1 (ko) * 2013-10-01 2017-11-13 노파르티스 아게 암의 치료를 위한 아푸레세르팁과 조합된 엔잘루타미드
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
JOP20190244A1 (ar) 2017-04-13 2019-10-13 Janssen Pharmaceutica Nv تركيبة علاجية لسرطان البروستاتا
CN111479560A (zh) 2017-10-16 2020-07-31 阿拉贡药品公司 用于治疗非转移性去势难治性前列腺癌的抗雄激素
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
EP0633893B1 (en) 1992-03-31 1999-11-24 Btg International Limited 17-substituted steroids useful in cancer treatment
DK1276482T3 (da) * 2000-03-02 2008-05-26 Univ Pittsburgh Kombinationskemoterapi
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
WO2004037269A1 (en) * 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
JP2006515623A (ja) * 2003-01-13 2006-06-01 セダーズ−シナイ メディカル センター 化学療法剤としてのパリカルシトール
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
CN101528308A (zh) * 2006-08-25 2009-09-09 库伽尔生物科技公司 治疗癌症的方法和组合物

Also Published As

Publication number Publication date
JP6445123B2 (ja) 2018-12-26
IL197211A0 (en) 2009-12-24
SI2061561T1 (sl) 2013-11-29
CY1124221T1 (el) 2022-05-27
HK1131577A1 (en) 2010-01-29
CN104306977A (zh) 2015-01-28
AU2007287098A1 (en) 2008-02-28
KR20090059126A (ko) 2009-06-10
ES2869343T3 (es) 2021-10-25
JP6740497B2 (ja) 2020-08-12
DK2478907T3 (da) 2021-05-25
HRP20130961T1 (hr) 2013-11-22
PL2061561T3 (pl) 2013-12-31
AU2015221447B2 (en) 2016-12-15
HUE054495T2 (hu) 2021-09-28
AU2015221447B9 (en) 2017-07-20
KR20180003636A (ko) 2018-01-09
AU2018271331A1 (en) 2018-12-20
ES2428634T3 (es) 2013-11-08
JP2010501575A (ja) 2010-01-21
LT2478907T (lt) 2021-06-25
EP2478907A2 (en) 2012-07-25
NZ597830A (en) 2013-02-22
JP2012082215A (ja) 2012-04-26
HRP20210670T1 (hr) 2021-06-11
JP2018065859A (ja) 2018-04-26
WO2008024484A1 (en) 2008-02-28
CA2661422C (en) 2017-06-27
CA2661422A1 (en) 2008-02-28
JP2020114851A (ja) 2020-07-30
AU2007287098C1 (en) 2018-03-15
PL2478907T3 (pl) 2021-10-25
EP2478907B1 (en) 2021-04-14
IL257681A (en) 2018-04-30
EP2478907A3 (en) 2012-08-01
JP2019059750A (ja) 2019-04-18
RS62034B1 (sr) 2021-07-30
KR20150108946A (ko) 2015-09-30
AU2015221447A1 (en) 2015-09-17
JP2017052791A (ja) 2017-03-16
AU2021201649A1 (en) 2021-04-08
EP2061561B1 (en) 2013-07-10
SI2478907T1 (sl) 2021-08-31
JP2022185091A (ja) 2022-12-13
AU2017201764A1 (en) 2017-04-06
JP6053279B2 (ja) 2016-12-27
CN101528308A (zh) 2009-09-09
NO20200775A1 (no) 2009-03-20
JP2021038252A (ja) 2021-03-11
JP2015110577A (ja) 2015-06-18
AU2022206696A1 (en) 2022-08-11
EP3804730A1 (en) 2021-04-14
RS52956B (en) 2014-02-28
CY1115477T1 (el) 2017-01-04
AU2007287098B2 (en) 2013-08-15
PT2478907T (pt) 2021-05-26
EP2061561A1 (en) 2009-05-27
KR20200125776A (ko) 2020-11-04
NO20091190L (no) 2009-03-20
IL227746A0 (en) 2013-09-30
PT2061561E (pt) 2013-10-09

Similar Documents

Publication Publication Date Title
DK2061561T3 (da) Sammensætninger til behandling af cancer
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
BRPI0810634A2 (pt) Composições fungicidas
BRPI0716325A2 (pt) Composição antimicrobianas
FR2899479B1 (fr) Composition cicatrisante
DK3289876T3 (da) Forbindelser til behandling af cancer
BRPI0813775A2 (pt) Composição
DK3354276T3 (da) Sammensætninger til behandlingen af gastrointestinal inflammation
DK2121139T3 (da) Formulations for cancer treatment
ATE528048T1 (de) Schweisshemmende/desodorierende zusammensetzung
DE602008005353D1 (de) Lichtstreuende Zusammensetzungen
DK1849352T3 (da) Mejetærsker
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
BRPI0810557A2 (pt) composição
BRPI0722002A2 (pt) composições de desodorante
BRPI0716458A2 (pt) Composição de vulcanizado
DK2115069T3 (da) Varmehærdende sammensætning
ATE529092T1 (de) Antiperspirans-zusammensetzungen
BRPI0718428A2 (pt) Composição de ibuprofeno
BRPI0811274A2 (pt) Composição
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
DE502007002454D1 (de) Gleitelement
DE602007012648D1 (de) Härtbare Zusammensetzung
DK2173831T3 (da) Brøndbehandling
DE602007004820D1 (de) Härtbare Zusammensetzung